Cargando…

Do Naturally Occurring Antioxidants Protect Against Neurodegeneration of the Dopaminergic System? A Systematic Revision in Animal Models of Parkinson's Disease

Parkinson’s disease (PD) is the second most common neurodegenerative disease and is characterized by a significant decrease in dopamine levels, caused by progressive degeneration of the dopaminergic neurons in the nigrostriatal pathway. Multiple mechanisms have been implicated in its pathogenesis, i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Costas, Carmen, Faro, Lilian R.F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers 2022
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413795/ https://www.ncbi.nlm.nih.gov/pubmed/33882808 http://dx.doi.org/10.2174/1570159X19666210421092725

Ejemplares similares

Theory of mind deficits in Parkinson’s disease are not modulated by dopaminergic medication
por: Usnich, Tatiana, et al.
Publicado: (2023)

In vivo Illustration of Altered Dopaminergic and GABAergic Systems in Early Parkinson's Disease
por: Takashima, Hirotsugu, et al.
Publicado: (2022)

Dopaminergic Modulation of Sensory Attenuation in Parkinson's Disease: Is There an Underlying Modulation of Beta Power?
por: Macerollo, Antonella, et al.
Publicado: (2019)

Ablation of RIP3 protects from dopaminergic neurodegeneration in experimental Parkinson’s disease
por: Dionísio, Pedro A., et al.
Publicado: (2019)

Association Between Dopaminergic Medications and the Evolution of REM Sleep Behavior Disorder in Parkinson's Disease
por: Cao, Ruihua, et al.
Publicado: (2022)

Implications of dopaminergic medication withdrawal in Parkinson’s disease
por: Koschel, J., et al.
Publicado: (2021)

Do caffeine and more selective adenosine A(2A) receptor antagonists protect against dopaminergic neurodegeneration in Parkinson’s disease?
por: Chen, Jiang-Fan, et al.
Publicado: (2020)

Peripheral-Central Neuroimmune Crosstalk in Parkinson's Disease: What Do Patients and Animal Models Tell Us?
por: Fuzzati-Armentero, Marie Therese, et al.
Publicado: (2019)

Peripheral Inflammation Increases the Damage in Animal Models of Nigrostriatal Dopaminergic Neurodegeneration: Possible Implication in Parkinson's Disease Incidence
por: Machado, A., et al.
Publicado: (2011)

Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration
por: Tsika, Elpida, et al.
Publicado: (2014)

TFE3-Mediated Autophagy is Involved in Dopaminergic Neurodegeneration in Parkinson’s Disease
por: He, Xin, et al.
Publicado: (2021)

Dopaminergic Treatment Effects on Dysarthric Speech: Acoustic Analysis in a Cohort of Patients With Advanced Parkinson's Disease
por: Cavallieri, Francesco, et al.
Publicado: (2021)

miR-425 deficiency promotes necroptosis and dopaminergic neurodegeneration in Parkinson’s disease
por: Hu, Yong-Bo, et al.
Publicado: (2019)

VHL-1 inactivation and mitochondrial antioxidants rescue C. elegans dopaminergic neurodegeneration
por: Chen, Song, et al.
Publicado: (2019)

Dopaminergic Neurotransmission in Patients With Parkinson's Disease and Impulse Control Disorders: A Systematic Review and Meta-Analysis of PET and SPECT Studies
por: Martini, Alice, et al.
Publicado: (2018)

Sorbus alnifolia protects dopaminergic neurodegeneration in Caenorhabditis elegans
por: Cheon, Se-Myeong, et al.
Publicado: (2016)

Cell-penetrating, antioxidant SELENOT mimetic protects dopaminergic neurons and ameliorates motor dysfunction in Parkinson's disease animal models
por: Alsharif, Ifat, et al.
Publicado: (2020)

Nutritional Supplementation of Naturally Occurring Vitamin D to Improve Hemorrhagic Stroke Outcomes
por: Ashouri, Rani, et al.
Publicado: (2021)

Dopaminergic neurodegeneration in the substantia nigra is associated with olfactory dysfunction in mice models of Parkinson’s disease
por: Yuan, Yu, et al.
Publicado: (2023)

Parkinson’s disease: animal models and dopaminergic cell vulnerability
por: Blesa, Javier, et al.
Publicado: (2014)

Exploring Sphingolipid Implications in Neurodegeneration
por: Alessenko, Alice V., et al.
Publicado: (2020)

Glial Purinergic Signaling in Neurodegeneration
por: Pietrowski, Marie J., et al.
Publicado: (2021)

Mechanism of miR-132-3p Promoting Neuroinflammation and Dopaminergic Neurodegeneration in Parkinson’s Disease
por: Gong, Xin, et al.
Publicado: (2022)

The Crucial Roles of Pitx3 in Midbrain Dopaminergic Neuron Development and Parkinson’s Disease-Associated Neurodegeneration
por: Wang, Xin, et al.
Publicado: (2023)

Biomarkers of Neurodegeneration in Autoimmune-Mediated Encephalitis
por: Körtvelyessy, Peter, et al.
Publicado: (2018)

Is Generalized and Segmental Dystonia Accompanied by Impairments in the Dopaminergic System?
por: Ikezawa, Jun, et al.
Publicado: (2021)

Exercise-Induced Neuroprotection and Recovery of Motor Function in Animal Models of Parkinson's Disease
por: Palasz, Ewelina, et al.
Publicado: (2019)

Mitochondrial angiotensin receptors in dopaminergic neurons. Role in cell protection and aging-related vulnerability to neurodegeneration
por: Valenzuela, Rita, et al.
Publicado: (2016)

Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's Disease in Germany?
por: Heinzel, Sebastian, et al.
Publicado: (2018)

Chloroquine, the Coronavirus Crisis, and Neurodegeneration: A Perspective
por: Pedrioli, Giona, et al.
Publicado: (2020)

Editorial: The Cerebellum: From Vascular Disease to Neurodegeneration
por: Cocozza, Sirio
Publicado: (2021)

Editorial: Neuroinflammation and neurodegeneration from bench to bedside
por: Mohamed, Wael M. Y., et al.
Publicado: (2023)

Precision medicine in neurodegeneration: the IHI-PROMINENT project
por: Tate, Ashley, et al.
Publicado: (2023)

Sexually dimorphic mechanisms of VGLUT-mediated protection from dopaminergic neurodegeneration
por: Buck, Silas A., et al.
Publicado: (2023)

Substantia Nigra Hyperechogenicity Reflects the Progression of Dopaminergic Neurodegeneration in 6-OHDA Rat Model of Parkinson’s Disease
por: Zhang, Siyan, et al.
Publicado: (2020)

Voltage-Gated Proton Channel Hv1 Regulates Neuroinflammation and Dopaminergic Neurodegeneration in Parkinson’s Disease Models
por: Neal, Matthew L., et al.
Publicado: (2023)

Prosaposin PS18 reduces dopaminergic neurodegeneration in a 6-hydroxydopamine rat model of Parkinson’s disease
por: Wu, Kuo-Jen, et al.
Publicado: (2023)

Modeling of the Progressive Degradation of the Nigrostriatal Dopaminergic System in Mice to Study the Mechanisms of Neurodegeneration and Neuroplasticity in Parkinson’s Disease
por: Kolacheva, Anna, et al.
Publicado: (2022)

Fluorescence microscopy-based sensitive method to quantify dopaminergic neurodegeneration in a Drosophila model of Parkinson’s disease
por: Ayajuddin, Mohamad, et al.
Publicado: (2023)

Do Benzodiazepines Impair Motor and Nonmotor Symptoms in a Sample of Parkinson’s Disease Patients?
por: Gaztanaga, Wendy, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ergc0c82acgq6i6fdb2og9qps9